Аңдатпа
The paper reports the study of the effect of the Kazakh mmedicine Kezimuk granules on himoral immunity, cell-medicated immunity and immunological function of cyclophosphamide immunosupressed mice. 60 SPF Kunming mice, half male and half female, were randomly divided into 6 groups. Each group contains 10 mice: Respectively the normal group (saline solution) comparing to the control group (Yupingfeng granules) and the model group (saline solution) comparing to high, medium and low dose Kezimuk granule groups. The high, medium and low dose ,2.72g/kg, 1.36g/kg, and 0.68g/kg, of Kezimuk were equivalent to 4, 9, and 18 times of it and the recommended dose was calculated through the basis of relative surface of mice, referring to humans. Doses were daily intaken by intragastric administration for 2 weeks. After drug administration from the seventh day to ninth day ,for 3 days, each group, except the normal control group, received intra-peritoneal injections,pyrophosphate,at a dose of 50mg/kg to induce the immunocompromise. The thymus index, spleen index, serum IL-2 content and the body weight of the mice, were measured to observe the effect of each dose of Kezimuk granules on pyrophosphate to induce immunosuppression of the cellular immunity and humoral immunity in the mice. Comparing to the model group Kezimuk granules significantly increase the thymus index and spleen coefficient and remarkably increase the index of B Lymphocyte proliferation, T Lymphocyte proliferation and the serum IL-2 content as well as body weight of immunocompromised mice (P<0.05); the results for the middle and high dose of Kezimuk granule groups were significantly higher than the model group (P<0.05). Kezimuk granule might have a protective effect on immunocompromised mice and improve immunologic function.